A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results

Michelle J. Khan, University of Alabama Birmingham
L. Stewart Massad, Washington Univ
Walter Kinney, Permanente Med Grp Inc
Michael A. Gold, Univ Oklahoma
EJ Mayeaux, University of South Carolina
Teresa M. Darragh, University of California San Francisco
Philip E. Castle, Albert Einstein College of Medicine
David Chelmow, Virginia Commonwealth University
Herschel Lawson, Emory University
Warner K. Huh, University of Alabama Birmingham

Journal Title: Gynecologic Oncology
Volume: Volume 141, Number 2
Publisher: Elsevier | 2016-05-01, Pages 364-370
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1016/j.ygyno.2015.11.023
Permanent URL: https://pid.emory.edu/ark:/25593/s2nj3

Final published version: http://dx.doi.org/10.1016/j.ygyno.2015.11.023

Copyright information:
© 2015 The Authors.
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Accessed November 6, 2018 9:16 AM EST
A common clinical dilemma: management of abnormal vaginal cytology and human papillomavirus test results

Michelle J. Khan, MD, MPH¹, L. Stewart Massad, MD², Walter Kinney, MD³, Michael A. Gold, MD⁴, EJ Mayeaux Jr., MD⁵, Teresa M. Darragh, MD⁵, Philip E. Castle, PhD, MPH⁷, David Chelmow, MD⁸, Herschel W. Lawson, MD⁹, and Warner K. Huh, MD¹⁰

¹Division of Women’s Reproductive Healthcare, Department of Obstetrics and Gynecology, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA
²Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO, USA
³Department of Women’s Health, the Permanente Medical Group, Sacramento, California, USA
⁴Tulsa Cancer Institute and University of Oklahoma School of Community Medicine
⁵Department of Family and Preventive Medicine and Department of Obstetrics and Gynecology, University of South Carolina School of Medicine, Columbia, SC, USA
⁶Department of Clinical Pathology, University of California, San Francisco, CA, USA
⁷Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA
⁸Department of Obstetrics and Gynecology, Virginia Commonwealth University, Richmond, VA
⁹Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA
¹⁰Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA

Abstract

Objective—Vaginal cancer is an uncommon cancer of the lower genital tract, and standardized screening is not recommended. Risk factors for vaginal cancer include a history of other lower genital tract neoplasia or cancer, smoking, immunosuppression, and exposure to diethylstilbestrol in utero. Although cervical cancer screening after total hysterectomy for benign disease is not recommended, many women inappropriately undergo vaginal cytology and/or human papillomavirus (hrHPV) tests, and clinicians are faced with managing their abnormal results. Our
objective is to review the literature on vaginal cytology and hrHPV testing and to develop
guidance for the management of abnormal vaginal screening tests.

**Methods**—An electronic search of the PubMed database through 2015 was performed. Articles
describing vaginal cytology or vaginal hrHPV testing were reviewed, and diagnostic accuracy of
these tests when available was noted.

**Results**—The available literature was too limited to develop evidence-based recommendations
for managing abnormal vaginal cytology and hrHPV screening tests. However, the data did show
that 1) the risk of vaginal cancer in women after hysterectomy is extremely low, justifying the
recommendation against routine screening, and 2) in women for whom surveillance is
recommended, e.g. women post-treatment for cervical precancer or cancer, hrHPV testing may be
useful in identification of vaginal cancer precursors.

**Conclusion**—Vaginal cancer is rare, and asymptomatic low-risk women should not be screened.
An algorithm based on expert opinion is proposed for managing women with abnormal vaginal
test results.

**Keywords**
n vaginal cytology; HPV; vaginal cancer; VaIN

**INTRODUCTION**

Vaginal cancer is a rare human papillomavirus (HPV) – associated gynecologic disease,
accounting for approximately 1–4% of cancers of the female genital tract.\(^{1}\) A recent report
from the National Program of Cancer Registries and the Surveillance, Epidemiology, and
End Results Program estimated that 729 cases of vaginal cancer occurred each year from
2004–2008, with approximately 500 attributable to HPV.\(^ {2}\) The reported incidence rate of
vaginal cancer is 0.4–0.6 per 100,000 women; by comparison, the incidence rate for cervical
cancer in the United States is 7.7 per 100,000 women.\(^ {2,3}\) The majority of vaginal cancers
are of squamous cell histology; adenocarcinomas and melanomas are seen in smaller
numbers.

High-grade squamous intraepithelial lesion (HSIL), or vaginal intraepithelial neoplasia
(VaIN) grades 2/3, is a precancerous lesion analogous to HSIL/cervical intraepithelial
neoplasia (CIN) grades 2/3.\(^ {4-6}\) Low-grade squamous intraepithelial lesion (LSIL), or
VaIN1, is a benign manifestation of HPV infection. Although natural history data on VaIN
are scarce, it is thought that invasive vaginal cancer, like invasive cervical cancer, is caused
by persistent high-risk HPV infection.\(^ {7}\) Other known risk factors for vaginal cancer
include age at first intercourse <17 years old, ≥5 lifetime number of sexual partners,
immunosuppression, smoking, pelvic radiation therapy, and exposure to diethylstilbestrol
(DES) \textit{in utero}.\(^ {4,8}\) Women who have had cervical cancer are also at significantly
increased risk of developing vaginal cancer.\(^ {7}\) Age is also a risk factor for precancerous
lesions of the vagina: HSIL/VaIN2/3 was found more often in women >50 years old
compared to LSIL/VaIN1 (mean age of 45 years).\(^ {9}\) The Centers for Disease Control and
Prevention reported the mean age at diagnosis of vaginal cancer was 69 years, two decades
later than the mean age of cervical cancer of 48 years.\(^ {10}\)
There are no recent population-based studies that provide an accurate estimation of the incidence of VaIN, but extrapolating from older data, the incidence is thought to be approximately 0.2–0.3 per 100,000 women in the United States.\(^{(11)}\) VaIN incidence may be rising as a result of increased sexual exposure to hrHPV with changing sexual behavior over the past several decades, as well as with improved detection with widespread sensitive cervical cancer screening tests and colposcopy.\(^{(12)}\) The estimated progression rate of VaIN to vaginal cancer ranges from 0–9% in 5 different studies. These studies included cases of women with VaIN grades 1, 2, and 3 who progressed to invasive vaginal cancer. These reported rates of progression are much lower than the demonstrated up to 30% progression rate for CIN3 to invasive cervical cancer.\(^{(1, 7–9, 13–16)}\)

Due to the rarity of vaginal cancer, there are currently no formal guidelines recommending screening for vaginal cancer in the general population (Table 1). In fact, research articles and professional society guidelines recommend against vaginal cancer screening in women post hysterectomy for benign disease and in women posthysterectomy for cancers other than cervical cancer.\(^{(17–19)}\) However, current cervical cancer screening guidelines do recommend that high-risk groups such as women who have had cervical precancer (HSIL/CIN2/3) or invasive cervical cancer undergo continued surveillance testing for at least 20 years after treatment.\(^{(17)}\) By this definition, women with a history of cervical precancer who subsequently undergo hysterectomy will still require vaginal cytology screening for at least 20 years after their treatment for cervical precancer.

Despite guidelines recommending against vaginal cancer screening for women posthysterectomy for benign conditions and NO history of precancer (Table 1), many such women have cytology and/or cotesting (cytology + hrHPV testing) performed.\(^{(17, 20)}\) This leaves clinicians with the dilemma of how to manage these abnormal vaginal screening tests. The objective of this article is to review the literature on vaginal cytology and hrHPV testing and their accuracy in prediction of VaIN/cancer, and to provide guidance on how to best manage women who were screened inappropriately after hysterectomy, as well as women undergoing surveillance after treatment for cervical HSIL/cancer. For women screened inappropriately, we aim to provide guidance for discontinuation of further testing.

Unlike the consensus management guidelines for abnormal cervical cancer screening results and diagnosed cervical precancer published by the ASCCP, this guidance is based expressly on expert opinion, because there are no large clinical trials or rigorous epidemiologic studies of vaginal cancer screening on which to base our recommendations.

**METHODS**

We performed a search of the PubMed database through June 2015 using the keywords “vaginal intraepithelial neoplasia, vaginal dysplasia, HPV DNA testing, hysterectomy, vaginal cancer, and HPV/human papillomavirus.” We also searched the references of retrieved articles. Articles were reviewed if they reported on vaginal screening tests and reviewed at least 20 histologically-confirmed cases of vaginal cancer and/or VaIN. Studies were excluded if they did not distinguish between CIN and VaIN, to be able to extract data for VaIN alone. Abstracts, letters to the editor, and studies written in any language other than...
English were excluded. For each study meeting the inclusion criteria, data were extracted about author, year of publication, country of publication, sample size, presence of hysterectomy, cytologic and histopathologic information, HPV test used and results including genotyping if available.

RESULTS

A total of 2,478 titles were retrieved using the search terms described. The majority were excluded by their title and the remainder after reviewing the abstract or complete article. A total of 325 abstracts were reviewed and 18 studies met inclusion criteria after full text review (Supplemental Table S1).

HPV attribution and genotype distribution among VaIN and vaginal cancers

Smith et al. performed a systematic review of the literature and looked at the HPV attribution among 66 LSIL/VaIN1, 166 HSIL/VaIN2/3, and 83 invasive vaginal cancer cases. (5) Overall HPV prevalence was 98.5% in LSIL/VaIN1, 92.6% in HSIL/VaIN 2/3, and 65.5% in invasive vaginal cancer. All of the HPV-positive vaginal cancers and the vast majority of the HPV-positive HSIL/VaIN2/3 lesions tested positive for high-risk HPV types. Another concurrent meta-analysis found HPV attribution of 100% in LSIL/VaIN1, 90.1% in HSIL/VaIN 2/3, and 69.9% in invasive vaginal cancer.(21) A Swedish study of 69 vaginal cancer cases found HPV positivity in 37 (53.6%) cases, with 70.3% testing positive for HPV16 and 5.4% for HPV18, 31, 33, and 52. In a recent study of invasive vaginal cancers from population-based registries in the United States, hrHPV testing was performed on 60 cases and 75% tested positive for hrHPV. (22) Finally, in a worldwide study of 189 HSIL/VaIN2/3 and 408 invasive vaginal cancer cases that were individually tested for HPV, overall HPV positivity was found in 74% of the invasive vaginal cancers and 96% of the HSIL/VaIN2/3. (23) In all of these studies, HPV16 was the most common hrHPV type detected in VaIN and vaginal cancers.(5, 21, 23–25) The next most common hrHPV types were HPV18, 31, 33, and 52, although their prevalence was much lower than HPV16.

In summary, hrHPV positivity was found in 99 – 100% of LSIL/VaIN1, in 90 – 96% of HSIL/VaIN2/3, and in 64–75% of invasive vaginal cancers.

Vaginal cytology for detection of VaIN

Few studies have examined the use of vaginal cytology for detection of VaIN. The largest cohort that examined vaginal cytology results following hysterectomy was by Pearce et al in 1996. (26) A total of 9,610 vaginal cytology samples were obtained from 5,682 women post-hysterectomy for benign gynecologic disease over a three year period, for an average of 1.7 smears per woman. Of the 9,610 cytology samples, 104 (1.1%) were abnormal, including 0.5% atypical squamous cells of undetermined significance (ASC-US), 0.5% LSIL, 0.1% HSIL, and 0.02% squamous cell carcinoma (SCC). There were no biopsy-proven vaginal cancer cases and there were only 6 cases of LSIL/VaIN1 or HSIL/VaIN2. The positive predictive value of vaginal cytology was 0% for HSIL/VaIN3 and vaginal cancer and 6.3% for VaIN1/2.
Frega et al. studied 830 women who had a hysterectomy and on whom they performed vaginal cytology, colposcopy with biopsy of lesions, and hrHPV testing via PCR over a follow-up of 2–5 years (mean 3 years). (27) Thirty women had HSIL/VaIN2/3, of whom 25 (83.3%) tested “positive” by cytology, the definition of positive cytology was not defined by the authors. Of the two women that developed cancer following VaIN3, both had been positive by cytology at their initial VaIN3 detection.

A study by So et al. reported on 48 women with VaIN, of which 37 had follow-up information. (9) The women were followed every 3–6 months by colposcopy, cytology, and hrHPV testing for a mean of 30 months (range 12–72 months). On follow-up after treatment, 70.3% of patients had resolution of the VaIN lesion(s) and none progressed to invasive vaginal cancer. The authors reported no significant association of cytologic result with grade of VaIN at the initial visit. They combined “within normal limits” and ASC-US into one category and LSIL and HSIL into another, and reported that the diagnostic accuracy of cytology for diagnosis of persistent VaIN at a threshold of $\leq$ SIL was: sensitivity 18.2%, specificity 96.2%, positive predictive value (PPV) 66.7%, and negative predictive value (NPV) 73.5%.

Bansal et al. retrieved test information on 2,892 women with post-hysterectomy vaginal cytology and HPV testing data in the pathology archives over a four-year period. (28) Interestingly, 1,320 (45.6%) of the cytologic specimens were reported to contain a squamous cell abnormality, including 1,125 (85%) ASC-US, 148 (5.1%) LSIL, 36 (3%) atypical squamous cells cannot rule out high-grade (ASC-H), and 11 (1%) HSIL. Of the 148 women with LSIL, 76.4% (95% CI 69.5–83.2%) had a positive high-risk HPV test. They focused the analysis on 59 women with LSIL vaginal cytology who were followed for 0.2 to 43 months (median 13 months) and had follow-up histology. They found that 41 (69.5%) were diagnosed with LSIL/VaIN1, and 7 (14.6%; 0.2% of all the cytology samples) were diagnosed with HSIL/VaIN2/3. They concluded that the positive predictive value (PPV) of LSIL vaginal cytology for HSIL/VaIN2/3 is 14.3%.

In summary, a precise estimate of the accuracy of vaginal cytology for prediction of HSIL/VaIN2/3 is limited by the few available studies. The sensitivity was 83% in one prospective study. (27) The PPV of cytology for HSIL/VaIN2/3 ranges from 0–14%.

**HPV testing for detection of VaIN**

There is currently no FDA-approved hrHPV test for use in screening for vaginal cancer or precancer; however, women who receive inappropriate screening after hysterectomy for benign disease often have hrHPV or cotesting results that require interpretation and management.

HPV infection of the vagina is as common as HPV infection of the cervix. Castle et al. studied the prevalence of vaginal HPV in 569 women post-hysterectomy within a natural history cohort in Guanacaste, Costa Rica, and compared age-standardized prevalence of HPV in vaginal specimens to cervical specimens from 6,098 women who did not have a hysterectomy. (29) The prevalence of high-risk HPV was not significantly different in women who had undergone hysterectomy (9.5%, 95% CI 5.0%–14.1%) compared with those who
had an intact uterus (9.3%, 95% CI 8.6% – 10.0%). Another study by Castle et al. at Kaiser Permanente in Portland, Oregon, compared HPV prevalence among women who had a hysterectomy to those who had not, and they found no significant differences in high-risk HPV between the 2 groups (4.5% in women who had undergone hysterectomy; 6.5% in those who had not).(30)

Only one prospective cohort study has examined hrHPV prevalence and its relation to VaIN and vaginal cancer. Frega et al. studied 830 women as noted above.(27) The majority of the women (728/830) had hysterectomy for a gynecologic malignancy, so this was a high-risk population for vaginal cancer. Forty-four cases of VaIN were reported (5.3% of the study population; 14 VaIN1, 24 VaIN2, 6 VaIN3), and all (100%) tested hrHPV positive with 91% testing positive for HPV16 and 9% testing positive for HPV18. Two of the 6 (33%; 0.2% of the entire study population) women with HSIL/VaIN3 progressed to cancer over a three-year follow-up period. HrHPV testing had a sensitivity of 90%, specificity 78%, PPV 56%, and NPV 92% for persistence/progression of VaIN.

Most other studies that evaluated hrHPV testing in VaIN lesions were retrospective pathology studies that performed HPV testing on vaginal biopsy specimens.(4, 31–35) Several of these studies were included in the systematic reviews of HPV attribution in VaIN and vaginal cancers and we will not discuss them further.(5, 21, 25) Regardless, the findings illustrate the prevalence of hrHPV in the vagina and may shed some light on the utility of hrHPV testing for detection of VaIN.

In the study by So et al. discussed above, 48 women with VaIN were tested for hrHPV and were followed for up to 72 months.(9) They found that 74.3%, 85.7% and 100% of LSIL/VaIN1, HSIL/VaIN2, and HSIL/VaIN3 lesions, respectively, tested positive for hrHPV. This was the only study to report on HPV viral load, and they found higher loads in HSIL/VaIN2/3 compared with LSIL/VaIN1 (p=0.009). Higher HPV viral loads were also found in the women with persistent VaIN compared with the women who had regression of their lesion(s) (p<0.001). They calculated the diagnostic accuracy of hrHPV testing for prediction of persistent VaIN: sensitivity 81.8%, specificity 88.5%, PPV 75.0%, and NPV 92.0%.

In the Bansal study noted above, 34/148 (82.9%) of the LSIL/VaIN1 cases and all of the 11 HSIL/VaIN2/3 cases tested positive for hrHPV.(28) The calculated sensitivity of hrHPV testing for prediction of HSIL/VaIN2/3 was 100%, specificity 21%, PPV 15%, and negative predictive value 100%.

Chao et al. performed HPV testing using PCR on 394 VaIN tissue blocks.(36) They found that 69.3% of VaIN tissue blocks tested positive for HPV, and of those that tested positive, 17.9% had multiple HPV types present. The most common types present in the HPV-positive tissue blocks were HPV16 (35.5%), HPV58 (9.9%), HPV39 (8.4%), HPV33 (7.3%), and HPV53 (7.0%).

In summary, hrHPV infection of the vagina is just as common in women posthysterectomy as those with an intact uterus. A precise estimate of the accuracy of vaginal hrHPV testing for prediction of HSIL/VaIN2/3 is limited by the few available studies. The sensitivity ranges from 90% for prediction of VaIN persistence/progression to 100% for prediction of
**DISCUSSION/GUIDANCE**

**Management of abnormal vaginal screening tests**

Expert authors recommend applying some recommendations from cervical cancer prevention guidelines to management of abnormal vaginal screening tests. For example, although hrHPV testing is not FDA-approved for use on specimens obtained from the vagina, given the high prevalence of hrHPV in HSIL/VaIN/3 and vaginal cancer, the negative predictive value of a hrHPV test is very high and therefore reassuring that there is low risk of vaginal cancer. Accordingly, healthy asymptomatic women with negative hrHPV testing and a negative cytology are at extremely low risk and do not require future testing if they have had hysterectomy for benign disease and have no history of cervical precancer or cancer. The positive predictive value of hrHPV testing for vaginal cancer and its precursors is less clear, since few studies have reported on hrHPV testing in women without histologically-confirmed VaIN, but it is expected to be low as noted in the preceding section.

As noted above in two of the studies that reported on vaginal cytology after hysterectomy, the PPV of cytology for HSIL/VaIN2/3 ranges from 0–6% in the Pearce study, to 14% in the Bansal study. The PPV from the Bansal study likely represents an overestimate, since only 40% of women with LSIL had biopsies done and case histories were unknown, so decision for biopsy might have been biased toward higher risk women. It is clear from this study that vaginal cytologic abnormalities are common in women post-hysterectomy; because hysterectomy indications and prior CIN were unknown, the generalizability of this result to most women who have had hysterectomies is unclear. The PPV for persistent VaIN was 67% in the So study, but it is unclear which grade of VaIN was persistent in the 11 women. Given the low PPV estimates for both vaginal cytology and hrHPV testing, we favor a conservative approach to management of abnormal vaginal tests.

Although we can use some of the knowledge we have gained from studies of the natural history of HPV-related cervical lesions to decide how to manage women with VaIN, it is important to keep in mind that vaginal cancer incidence is an order of magnitude lower than cervical cancer incidence, and as such we must be careful not to over-screen and over-evaluate women for a rare condition. Women with a history of recent treatment for HSIL/CIN2/3 or cervical cancer must undergo surveillance according to national guidelines. The following guidance applies to women without a history of HSIL/CIN2/3 or cancer who were inappropriately screened using cytology or cotesting, or those with a history of HSIL/CIN2/3 or cancer who have completed the recommended surveillance after treatment and are now in follow-up for at least 20 years post-treatment. Although women post-treatment for HSIL or cancer are at higher risk for vaginal cancer than women post-hysterectomy for benign disease, most disease recurrence occurs within the first 2–3 years post-treatment, and their risk goes down substantially after repetitive negative screening tests. We therefore reasoned that the women post-treatment for HSIL or cancer can be managed similarly as the low-risk women after they have had negative post-treatment surveillance tests and are back to routine surveillance for at least 20 years.
An ASC-US result on vaginal cytology, similar to cervical ASC-US, is a nonspecific equivocal result and as such should have some type of triage test to lead to the next step in management, i.e., vaginal colposcopy. An LSIL result is indicative of a benign HPV infection and is likely to test hrHPV positive. We propose that vaginal colposcopy should be deferred and vaginal cotesting be repeated in one year for women with either ASC-US or LSIL vaginal cytology, and, if persistently abnormal or hrHPV positive (hrHPV+), the woman should undergo vaginal colposcopy with biopsy of any lesions (Figure 1).

Alternatively, since most HPV-positive vaginal cancers are HPV16/18 positive, genotyping can be done, with immediate colposcopy if HPV16/18 positive with ASC-US or LSIL and observation for up to two years in women who are HPV16/18 positive with negative cytology or women who are HPV16/18 negative with ASC-US or LSIL. Women who cotest negative/negative can return to routine screening, which should be cessation of screening if they had hysterectomy for benign disease or continued surveillance for 20 years if they have had HSIL or cancer. If HPV testing is not available, cytology can be repeated one year after an initial ASC-US or LSIL, and if any abnormality is reported (e.g., ≥ASC-US) the woman should be referred for colposcopy. Given the lower sensitivity and negative predictive value of cytology compared with cotesting, two negative cytology results should be documented before returning to routine surveillance or cessation of screening.

High-grade squamous intraepithelial lesion (HSIL) vaginal cytology should prompt timely vaginal colposcopy with biopsy of any suspicious-appearing lesions. As noted in our literature review, HSIL vaginal cytology is rarely encountered. If vaginal colposcopy is negative after HSIL cytology, we would recommend repeat vaginal cytology and colposcopy in 6–12 months. No evidence exists to guide management of women with atypical glandular cells (AGC) or atypical squamous cells cannot rule out high-grade (ASC-H) cytology after hysterectomy. We recommend the same management as after HSIL cytology.

Finally, women with a positive hrHPV test and negative cytology should have repeat cytology or co-testing in one year. Any abnormalities at the repeat test should prompt vaginal colposcopy.

This guidance for follow-up of women with abnormal vaginal testing results also apply to women who are appropriately undergoing vaginal surveillance, with the caveat that surveillance should continue for at least 20 years after treatment for HSIL or cancer even after negative/negative cotesting.(37) National guidelines do not specifically state the interval for surveillance after the first 5 years post-treatment, but we would propose that women with negative/negative cotesting undergo surveillance tests at three-year intervals. (37) This guidance applies only to asymptomatic women and should not be extended to women with abnormal vaginal cytology who have symptoms, especially bleeding, or visible vaginal lesions.

**Vaginal colposcopy**

Most colposcopists have plentiful experience with examining the cervix, but vaginal lesions are less commonly encountered in clinical practice. It is important to remember certain principles when performing a colposcopy of the vagina.(41) Unlike the cervix, the vagina is not easily visualized in a static colposcopy. There are multiple folds and areas covered by...
the speculum requiring that the colposcopist manipulate the speculum during the colposcopic exam to view all of the walls of the vagina as well as the fornices. It is important to apply a dilute solution (3–5%) of acetic acid to the entire vaginal mucosa, and to wait at the minimum 1–2 minutes for acetowhite changes to appear. The colposcopic findings in vaginal lesions include acetowhite epithelium, punctation, color changes, and ulceration; mosaicism is rarely seen in the vagina. In the absence of iodine allergy, Lugol’s iodine should also be applied to confirm the presence or absence of an abnormal area of epithelium; Lugol’s nonstaining areas are seen in VaIN lesions. The most common place for VaIN to be present in a woman posthysterectomy is at the vaginal cuff. It is important to take a biopsy when a lesion is identified at vaginal colposcopy, since the histology will help to distinguish between normal epithelium, a benign, productive VaIN1 lesion, and a true cancer precursor. Lesions in the upper two-thirds of the vagina do not generally require anesthetic prebiopsy; however there are more nerve endings in the lower one-third of the vagina and topical or injectable anesthetic may be needed prior to biopsy. Vaginal colposcopy should be done by clinicians with higher volume experience in vaginal colposcopy.

Treatment for VaIN

VaIN can be treated by several different modalities and there is currently no standard of care as to which method is superior. The choice of treatment method should therefore take into account the patient’s preference as well as the experience and training of the treating provider (Table 2). In general, it is not recommended to treat LSIL/VaIN1 lesions since these lesions usually represent a benign productive HPV infection; however, there may be clinical situations in which treatment is preferred such as cosmetic treatment for bulky or bleeding warts.

Treatment is recommended for histologic HSIL/VaIN3, which is considered the precursor lesion to vaginal cancer. VaIN2 represents an equivocal diagnosis that has the potential to regress; if p16 immunostaining is performed and negative, it would be reasonable to conservatively follow patients with VaIN2. However, VaIN2 with positive p16 staining should be considered a true precancer and should be treated.

Several studies have reported on the various methods of treatment, which include topical medications (imiquimod, 5-fluorouracil, trichloroacetic acid, intravaginal estrogen), CO2 laser ablation, excision/vaginectomy, cavitational ultrasonic surgical aspiration, and radiation therapy.(42, 43) In our experience, the most common therapies include CO2 laser ablation and excision/vaginectomy. Topical options can be considered for patients who are not good surgical candidates, however side effects such as burning and irritation may limit their tolerance. Patients with vaginal cancer should be referred to a gynecologic oncologist for further management.

After a diagnosis of LSIL/VaIN1 or p16 negative VaIN2, we would recommend cotesting at 12 months. If the cotest is negative/negative, we recommend stopping further screening in women who were inappropriately screened, and continue annual cytology or every three-year cotesting in women post-treatment for HSIL or cancer. For women with persistent LSIL/VaIN1 beyond 2 years without prior HSIL or cancer, it would be reasonable to extend the screening interval to every 2–3 years. After treatment for HSIL/VaIN3 or p16+ VaIN2,
we recommend cotesting in 12 months and vaginal colposcopy if the result is hrHPV+ or ≤LSIL cytology.

Conclusion

Vaginal cancer is a rare HPV-related malignancy that may be detected through vaginal cytology or HPV testing. It is not recommended to screen the general population for vaginal cancer. Women in high-risk groups who require close surveillance after treatment for cervical precancer or cancer should be followed per national guidelines. Women with abnormal vaginal screening tests post hysterectomy are at low risk of having HSIL/VaIN2/3 and at even lower risk of having invasive vaginal cancer. We propose an algorithm to identify those women at highest risk that should undergo colposcopy and biopsy of vaginal lesions. These include women with HSIL, ASC-H, or AGC vaginal cytology and women with persistent hrHPV infection ≥1 year or persistent ASC-US/LSIL ≥1 year. These recommendations are based on expert opinion, since evidence from prospective VaIN and vaginal cancer trials are lacking. Clinicians can use these recommendations to manage their average-risk patients with abnormal vaginal screening tests. Consultation with an expert should be considered for high-risk women or for situations outside the scope of this guidance.

Our exploration of the literature on VaIN and vaginal screening tests has defined areas of uncertainty. Further research on these topics is needed. In addition to conventional retrospective and cohort studies, this might be an opportunity to explore institutional or administrative databases for outcomes after an abnormal vaginal cytology or hrHPV test and after a diagnosis of VaIN. Although subject to the usual limitations of database studies, such as approach would harness larger numbers of VaIN and vaginal cancers from which to examine the contribution of vaginal tests and better define the natural history of VaIN and vaginal cancer.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We would like to thank the ASCCP Board of Directors and the Editor-in-Chief of the Journal of Lower Genital Tract Disease for their assistance in editing the manuscript and providing feedback on earlier versions. We would also like to thank Ms. Kamaria Nelson and Dr. Brittany Lees for their assistance with the early PubMed searches. MJK was supported in this work by grants NCI P50 CA098252 (PI Wu/Huh) and AHRQ K12 HS023009 (PI Saag); this work does not represent the views of either funding agency. LSM (personal fees for review of malpractice cases); TMD (non-financial support from Hologic and honorarium paid to UCSF from Roche, TheVax Genetics, Ventana-Roche); PEC (non-financial support from MTM, BD, Roche, Qiagen, and personal fees from Cepheid, BD, Roche, Inovio, Teva Pharmaceuticals, ClearPath, Merck, Genticel, and GE Healthcare); WKH (personal fees from Merck Vaccines and TheVax).

References


<table>
<thead>
<tr>
<th>Highlights</th>
</tr>
</thead>
<tbody>
<tr>
<td>• After hysterectomy, HSIL and cancer of the vagina are rare.</td>
</tr>
<tr>
<td>• Vaginal cancer screening is not recommended, yet women receive vaginal testing requiring clinical management.</td>
</tr>
<tr>
<td>• We propose a conservative approach to management of abnormal vaginal cytology and/or high-risk HPV tests.</td>
</tr>
</tbody>
</table>
Figure 1.
Proposed management algorithm for abnormal vaginal cancer screening tests in women with a history of hysterectomy.
### Table 1

Current screening guidelines for vaginal cancer

<table>
<thead>
<tr>
<th>Population</th>
<th>Recommended screening method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy asymptomatic women with a cervix undergoing annual gynecologic</td>
<td>None; Cervical cancer screening per ASCCP/ASCP/ACS and USPSTF guidelines(16, 40)</td>
</tr>
<tr>
<td>exam; no prior history of cervical dysplasia</td>
<td></td>
</tr>
<tr>
<td>Healthy asymptomatic women post-hysterectomy for benign disease</td>
<td>None</td>
</tr>
<tr>
<td>undergoing annual gynecologic exam; no prior history of cervical dysplasia</td>
<td></td>
</tr>
<tr>
<td>Women with history of cervical precancer (CIN2, CIN2/3, or CIN3) with a</td>
<td>Cervical cancer screening per ASCCP 2013 management guidelines(34)</td>
</tr>
<tr>
<td>cervix</td>
<td></td>
</tr>
<tr>
<td>Women with history of cervical precancer or cervical cancer post-</td>
<td>Per ASCCP 2013 and NCCN management guidelines(34)</td>
</tr>
<tr>
<td>hysterectomy</td>
<td></td>
</tr>
</tbody>
</table>
Table 2
Proposed subsequent management of histopathologic VaIN/vaginal cancer.

<table>
<thead>
<tr>
<th>Biopsy result</th>
<th>Management</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>LSIL</td>
<td>Vaginal cotesting in one year; repeat colposcopy if abnormal results</td>
<td>For bulky warty disease can consider cosmetic treatment.</td>
</tr>
<tr>
<td>HSIL</td>
<td>Treatment per current best practice</td>
<td>May vary by site and could include laser ablation, excision/vaginectomy, topical treatment. Referral to gynecologic oncologist for large or complex lesions.</td>
</tr>
<tr>
<td>Invasive carcinoma</td>
<td>Treatment per current best practice</td>
<td>Referral to gynecologic oncologist.</td>
</tr>
</tbody>
</table>

* For persistent LSIL beyond 2 years without progression to HSIL, can consider extending the screening and colposcopy interval to every 2–3 years particularly in patients with immunosuppression who may never eradicate HPV but remain at risk.

¶ See text regarding treatment for VaIN2.